Summary: Evaluated ramipril with or without vitamin E versus placebo in patients with coronary disease, stroke, peripheral arterial disease or diabetes. The primary composite endpoint of death from cardiovascular causes, myocardial infarction or stroke was significantly reduced. Each individual component of the composite endpoint was significantly reduced. There were fewer revascularization procedures, diabetic complications, new diabetes diagnosis and new heart failure diagnosis. Vitamin E had no benefit.
N Engl J Med. 2000 Jan 20;342(3):145-53.
N Engl J Med. 2000 Jan 20;342(3):154-60.
Circulation. 2003 Mar 11;107(9):1284-90.
Eponym: Heart Outcome Prevention Evaluation Trial